Year Published
- 2008 (0)
- 2009 (0)
- 2010 (1) Apply 2010 filter
- 2011 (0)
- 2012 (0)
- 2013 (0)
- 2014 (1) Apply 2014 filter
- 2015 (2) Apply 2015 filter
- 2016 (1) Apply 2016 filter
- (-) Remove 2017 filter 2017
- 2018 (1) Apply 2018 filter
- 2019 (0)
- 2020 (0)
- 2021 (0)
Research Topics
Populations
- Countries/Governments (0)
- Rural Populations (0)
- Smallholder Farmers (0)
- Women (0)
Types of Research
- Data Analysis (1) Apply Data Analysis filter
- Literature Review (1) Apply Literature Review filter
- Portfolio Review (0)
- Research Brief (0)
Geography
- East Africa Region and Selected Countries (1) Apply East Africa Region and Selected Countries filter
- (-) Remove Global filter Global
- South Asia Region and Selected Countries (1) Apply South Asia Region and Selected Countries filter
- Southern Africa Region and Selected Countries (1) Apply Southern Africa Region and Selected Countries filter
- Sub-Saharan Africa (1) Apply Sub-Saharan Africa filter
- West Africa Region and Selected Countries (1) Apply West Africa Region and Selected Countries filter
Dataset
- ASTI (1) Apply ASTI filter
- FAOSTAT (1) Apply FAOSTAT filter
- Farmer First (0)
- LSMS & LSMS-ISA (0)
- Other Datasets (0)
Current search
- (-) Remove Aid & Other Development Finance filter Aid & Other Development Finance
- (-) Remove Global filter Global
- (-) Remove Research & Development filter Research & Development
- (-) Remove 2017 filter 2017
The share of private sector funding, relative to public sector funding, for drug, vaccine, and diagnostic research & development (R&D) differs considerably across diseases. Private sector investment in overall health R&D exceeds $150 billion annually, but is largely concentrated on non-communicable chronic diseases with only an estimated $5.9 billion focused on "global health", targeting diseases that primarily affect low and middle-income countries (LMICs). We examine the evidence for five specific disincentives to private sector global health R&D investment: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed and sunk costs, and downstream rents from imperfect markets. Though all five may affect estimates of net returns from an investment decision, they are worth examining separately as each calls for a different intervention or remediation to change behavior.
An ongoing stream of EPAR research considers how public good characteristics of different types of research and development (R&D) and the motivations of different providers of R&D funding affect the relative advantages of alternative funding sources. For this project, we seek to summarize the key public good characteristics of R&D investment for agriculture in general and for different subsets of crops, and hypothesize how these characteristics might be expected to affect public, private, or philanthropic funders’ investment decisions.